<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004488</url>
  </required_header>
  <id_info>
    <org_study_id>199/14269</org_study_id>
    <secondary_id>CHMC-C-FDR001537</secondary_id>
    <secondary_id>CHMC-C-498</secondary_id>
    <nct_id>NCT00004488</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone
      density and focal bone lesions) in patients with Gaucher's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      This is a randomized, double blind, placebo controlled study.

      All patients receive oral calcium carbonate and cholecalciferol daily. Patients are
      randomized to receive oral alendronate sodium or placebo daily for 24 months.

      Patients are followed every 6 months for 2 years.

      Completion date provided represents the completion date of the grant per OOPD records
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date>September 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Gaucher's Disease</condition>
  <condition>Osteopenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium carbonate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of type 1 Gaucher's disease enzymatically proven to have acid beta glucosidase
        deficiency

        Must have been on stable dose (8-60 U/kg/every 2 weeks) of alglucerase enzyme therapy
        (Cerezyme or Ceredase) for at least 24 months

        Lumbar spine bone density below the mean for age, sex, and race

        --Prior/Concurrent Therapy--

        At least 6 months since prior medications that directly affect skeletal metabolism
        including, but not limited to, bisphosphonates, calcitonin, parathyroid hormone, or
        estrogen

        --Patient Characteristics--

        Renal: No chronic renal failure; No recurrent renal stones

        Esophageal: No history of dysphagia; No frequent heartburn; No esophagitis requiring
        treatment

        Other: No untreated hyperthyroidism or hypothyroidism; No concurrent hyperparathyroidism;
        No concurrent malignancy; No history of alcohol or drug abuse; Not pregnant; Negative
        pregnancy test; Fertile patients must use effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J. Wenstrup</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State University School of Medicine</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Gaucher's disease</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>rare disease</keyword>
  <keyword>sphingolipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

